Pharsight

Drugs that contain Tigecycline

1. Tigecycline patents expiration

Can you believe TIGECYCLINE received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9855335 AMNEAL Tigecycline composition for injection
Apr, 2033

(8 years from now)

US9855355 AMNEAL Method and device for plasma-treating hollow bodies
Apr, 2033

(8 years from now)

Market Authorisation Date: 02 August, 2018

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

TIGECYCLINE family patents

Family Patents

2. Tygacil patents expiration

TYGACIL's oppositions filed in EPO
TYGACIL Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE40183 PF PRISM CV 7-Substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
Apr, 2016

(8 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE40086 PF PRISM CV Method for treating bacterial infection with novel 7-substituted-9-substituted amino 6-demethyl-6-deoxytetracyclines
Jun, 2013

(10 years ago)

US9254328 PF PRISM CV Tigecycline compositions and methods of preparation
Mar, 2026

(1 year, 10 months from now)

US9694078 PF PRISM CV Tigecycline compositions and methods of preparation
Mar, 2026

(1 year, 10 months from now)

US10588975 PF PRISM CV Tigecycline compositions and methods of preparation
Mar, 2026

(1 year, 10 months from now)

US8975242 PF PRISM CV Tigecycline compositions and methods of preparation
Oct, 2028

(4 years from now)

US7879828 PF PRISM CV Tigecycline compositions and methods of preparation
Feb, 2029

(4 years from now)

US8372995 PF PRISM CV Crystalline solid forms of tigecycline and methods of preparing same
Oct, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-587) Mar 20, 2012
New Indication(I-588) Mar 20, 2012
New Indication(I-586) Mar 20, 2012

Market Authorisation Date: 15 June, 2005

Treatment: Method of treating bacterial infections

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

TYGACIL family patents

Family Patents